Verrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell

MT Newswires Live

09/19

Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.

The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.

Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.

Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2568926350"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568926350\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568926350?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-19 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568926350","market":"us","top_or_hot":-1,"title":"Verrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.</p><p>The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.</p><p>Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.</p><p>Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-19 20:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.</p><p>The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.</p><p>Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.</p><p>Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRCA","symbol_name":"Verrica Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568926350","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568926350","pubTimestamp":1758285308,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verrica Pharmaceuticals  said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRCA":"Verrica Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"Verrica表示开发合作伙伴获得日本对Ycanth的批准；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":1},"content_text":"Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}